News and Trends 14 Mar 2023 Astellas menopause study meets endpoints but leukemia drug disappoints There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […] March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Calliditas shares rise as phase 3 endpoints met in kidney disease trial Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial investigating the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas share prices rose 30% in the aftermath of the announcement. IgAN, or Berger’s disease, is […] March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Mar 2023Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine This week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products. The next breakthrough in cancer treatment? In our body, we have an innate immune […] March 9, 2023 Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Mar 2023 5 advancements in kidney disease research over the past year Prevalent in millions of people across the globe, kidney diseases manifest through various symptoms like blood and excess protein in urine, fluid retention causing swollen ankles, poor appetite and even the inability of the body to filter waste, resulting in acute kidney failure. To boost the research and development of treatments for kidney diseases, Kidney […] March 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2023 Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […] February 28, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 5 advancements in rare disease research over the past year There are more than 7,000 rare diseases that affect hundreds of millions of people worldwide. As Rare Disease Day is observed on February 28, here are five recent advancements that have transformed research and boosted the scope for the development of novel therapies. FDA approves tissue-agnostic therapies for rare cancers Tissue-agnostic drug development has been […] February 28, 2023 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2023 AELIX announces ‘important step towards HIV eradication’ AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies for HIV infection, has announced positive topline results from its AELIX-003 trial. The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX Therapeutics’ HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod […] February 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Depression trial gets green light Beckley Psytech Ltd has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site phase IIb study exploring the safety, efficacy and tolerability of two doses of its lead compound, BPL–003, in patients with treatment resistant depression (TRD). BPL-003 is the Beckley Psytech’s novel synthetic formulation of […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Positive topline data from sepsis trial Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In the study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 First patient enrolled in Pharming APSD trial Pharming Group N.V. says the first patient has been enrolled in its phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants. At […] February 21, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Positive results for INOVIO recurrent respiratory papillomatosis trial INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Immuno Cure starts HIV drug trial Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park, which specializes in PD-1-enhanced DNA vaccines and immunotherapies, has started its phase I clinical trial of ICVAX, a therapeutic vaccine against HIV/AIDS. The trial is taking place at the National Clinical Research Center for Infectious Diseases at The Third People’s […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email